At the risk of going down a rabbit hole, I'll respond.
First let me say, I am a small investor in the company since 2020 and an amateur at best, so my comments are my opinions only and should be taken as the opinion of an average mum & dad investor with limited experience.
My comment re the BOD salaries may have been a little broad, whereas my comment was more directed towards the Executive Directors who I feel are overpaid for where we are at as a company that is not making a profit and has not for many years.
As per our latest Annual Report, the BOD rem is shown below.
Without doing a bunch of research on salaries, below is an excerpt from the Hays Salary guide for 2023.
If we are to compare the Typical base salary of a CEO/MD for a company with turnover up to $50mil with our Executive Directors salaries, taking into account we have not turned a profit for many years, you could argue they are overpaid. We could argue for days on what the salary should look like, but I would suggest $250-$300K would be reasonable in addition to performance related bonuses such as additional shares.
I believe in the Tech, hence why I hold a small position. I understand this company has been built mainly off the back of the Pivac's IP etc. I also believe they are more than likely putting their heart and soul into the business, but the salaries they have been and continue to earn, with increases each year, just do not pass the pub test for me. Hence my original comment.
In my humble opinion, I would have expected the senior team to consider a salary freeze years ago until the company is a proven success and turning a profit.
Maybe I am wrong, but we are all entitled to our opinions.
- Forums
- ASX - By Stock
- are these p***ck's running a lifestyle co.?
FBR
fbr ltd
Add to My Watchlist
16.7%
!
0.5¢

At the risk of going down a rabbit hole, I'll respond.First let...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
0.5¢ |
Change
-0.001(16.7%) |
Mkt cap ! $28.44M |
Open | High | Low | Value | Volume |
0.6¢ | 0.6¢ | 0.5¢ | $15.49K | 2.783M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
134 | 57827566 | 0.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.6¢ | 31171404 | 40 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
128 | 56044243 | 0.005 |
48 | 18016280 | 0.004 |
23 | 13670332 | 0.003 |
9 | 11053500 | 0.002 |
17 | 75571999 | 0.001 |
Price($) | Vol. | No. |
---|---|---|
0.006 | 19115108 | 35 |
0.007 | 13024546 | 29 |
0.008 | 4837167 | 11 |
0.009 | 2275330 | 4 |
0.010 | 1539259 | 6 |
Last trade - 15.59pm 04/07/2025 (20 minute delay) ? |
Featured News
FBR (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online